Alimera Sciences, Inc.
(NASDAQ : ALIM)

( )
ALIM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.68%72.600.9%$609.77m
CELGCelgene Corporation
-0.17%127.431.1%$437.63m
AMGNAmgen Inc.
0.52%168.161.1%$408.10m
BIIBBiogen Inc.
0.49%283.151.2%$356.66m
REGNRegeneron Pharmaceuticals, Inc.
0.38%469.742.7%$318.78m
VRTXVertex Pharmaceuticals Incorporated
0.59%149.011.9%$229.76m
ILMNIllumina, Inc.
0.72%190.683.5%$214.74m
ALXNAlexion Pharmaceuticals, Inc.
0.02%133.431.9%$214.60m
INCYIncyte Corporation
-0.25%120.892.6%$131.76m
CLVSClovis Oncology, Inc.
-1.06%71.2018.0%$129.20m
KITEKite Pharma, Inc.
2.87%133.9116.1%$124.88m
TSROTESARO, Inc.
4.39%118.8614.7%$124.09m
AAgilent Technologies, Inc.
0.80%61.741.5%$120.48m
BMRNBioMarin Pharmaceutical Inc.
-0.40%80.604.4%$105.96m
SRPTSarepta Therapeutics, Inc.
-2.64%35.7319.8%$97.43m

Company Profile

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by Daniel C. Myers and David R. Holland and is headquartered in Alpharetta, GA.